Fengkai Xu

1.3k total citations
35 papers, 983 citations indexed

About

Fengkai Xu is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Fengkai Xu has authored 35 papers receiving a total of 983 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 14 papers in Pulmonary and Respiratory Medicine and 13 papers in Oncology. Recurrent topics in Fengkai Xu's work include RNA modifications and cancer (12 papers), Cancer-related gene regulation (9 papers) and Ferroptosis and cancer prognosis (7 papers). Fengkai Xu is often cited by papers focused on RNA modifications and cancer (12 papers), Cancer-related gene regulation (9 papers) and Ferroptosis and cancer prognosis (7 papers). Fengkai Xu collaborates with scholars based in China and Italy. Fengkai Xu's co-authors include Jie Gu, Chunlai Lu, Qiaoliang Zhu, Yin Li, Di Ge, Di Ge, Chunlai Lu, Yiwei Chu, Guangyin Zhao and Zongwu Lin and has published in prestigious journals such as Nature Communications, Hepatology and Scientific Reports.

In The Last Decade

Fengkai Xu

34 papers receiving 972 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fengkai Xu China 17 645 319 246 199 171 35 983
Mingjun Zheng China 17 573 0.9× 386 1.2× 196 0.8× 225 1.1× 121 0.7× 46 907
Maria O. Hernandez United States 5 528 0.8× 428 1.3× 378 1.5× 189 0.9× 284 1.7× 6 1.0k
Chengli Du China 17 719 1.1× 509 1.6× 236 1.0× 143 0.7× 79 0.5× 32 1.0k
Massimiliano Mellone United Kingdom 19 693 1.1× 494 1.5× 514 2.1× 135 0.7× 202 1.2× 24 1.2k
Yongshuo Liu China 13 512 0.8× 204 0.6× 283 1.2× 122 0.6× 95 0.6× 23 824
Madelon Paauwe Netherlands 13 456 0.7× 261 0.8× 380 1.5× 114 0.6× 131 0.8× 16 805
Cheng Zhou China 17 583 0.9× 436 1.4× 250 1.0× 145 0.7× 179 1.0× 51 1.1k
Rongfa Yuan China 19 559 0.9× 241 0.8× 337 1.4× 217 1.1× 124 0.7× 44 962
Wenwei Zhu China 11 650 1.0× 422 1.3× 318 1.3× 141 0.7× 239 1.4× 19 1.1k
Qing‐Mei He China 21 893 1.4× 648 2.0× 287 1.2× 139 0.7× 164 1.0× 44 1.3k

Countries citing papers authored by Fengkai Xu

Since Specialization
Citations

This map shows the geographic impact of Fengkai Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fengkai Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fengkai Xu more than expected).

Fields of papers citing papers by Fengkai Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fengkai Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fengkai Xu. The network helps show where Fengkai Xu may publish in the future.

Co-authorship network of co-authors of Fengkai Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Fengkai Xu. A scholar is included among the top collaborators of Fengkai Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fengkai Xu. Fengkai Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Huang, Xiaolong, Jiaqi Liang, Han Lin, et al.. (2025). Targeting inosine metabolism to enhance EGFR-targeted therapy in lung adenocarcinoma. Cancer Letters. 634. 218069–218069. 1 indexed citations
2.
Li, Yin, Li Luo, Yong Zhang, et al.. (2024). UPP1 promotes lung adenocarcinoma progression through the induction of an immunosuppressive microenvironment. Nature Communications. 15(1). 1200–1200. 28 indexed citations
3.
Zhang, Hongyu, Haoyu Wen, Qiaoliang Zhu, et al.. (2024). Genomic profiling and associated B cell lineages delineate the efficacy of neoadjuvant anti-PD-1-based therapy in oesophageal squamous cell carcinoma. EBioMedicine. 100. 104971–104971. 8 indexed citations
4.
Zhao, Guangyin, Hongyu Zhang, Fengkai Xu, et al.. (2023). Neoadjuvant pembrolizumab and chemotherapy in resectable clinical stage III non-small-cell lung cancer: a retrospective cohort study. Translational Lung Cancer Research. 12(1). 141–149. 6 indexed citations
5.
Ma, Teng, et al.. (2022). BIRC5 Modulates PD-L1 Expression and Immune Infiltration in Lung Adenocarcinoma. Journal of Cancer. 13(10). 3140–3150. 15 indexed citations
6.
Yang, Huiqin, Xing Jin, Tao Cheng, et al.. (2022). Comprehensive Genome-Scale Analysis of Esophageal Carcinoma With Esophageal Tissue-Resident Micro-Environment Discrepancy. Frontiers in Microbiology. 13. 859352–859352. 1 indexed citations
7.
Xu, Fengkai, Jie Gu, Yin Li, et al.. (2020). The effect of a novel slow-flow irrigation drainage tube on anastomotic leakage and empyema after the resection of esophageal or gastroesophageal junction cancer. Annals of Palliative Medicine. 10(2). 1560–1568. 1 indexed citations
8.
Li, Yin, Jie Gu, Fengkai Xu, et al.. (2019). Novel methylation-driven genes identified as prognostic indicators for lung squamous cell carcinoma.. PubMed Central. 11(4). 1997–2012. 16 indexed citations
9.
Zhu, Qiaoliang, Rongkui Luo, Jie Gu, et al.. (2019). High CXCR4 Expression Predicts a Poor Prognosis in Resected Lung Adenosquamous Carcinoma. Journal of Cancer. 11(4). 810–818. 9 indexed citations
10.
Xu, Fengkai, Shu Zhang, Jie Gu, et al.. (2019). TEX9 and eIF3b functionally synergize to promote the progression of esophageal squamous cell carcinoma. BMC Cancer. 19(1). 875–875. 13 indexed citations
11.
Xu, Fengkai, Jie Gu, Chunlai Lu, et al.. (2018). Calpain-2 Enhances Non-Small Cell Lung Cancer Progression and Chemoresistance to Paclitaxel via EGFR-pAKT Pathway. International Journal of Biological Sciences. 15(1). 127–137. 28 indexed citations
12.
Xu, Fengkai, Jie Gu, Lin Wang, et al.. (2018). Up-regulation Of EIF3e Is Associated With The Progression Of Esophageal Squamous Cell Carcinoma And Poor Prognosis In Patients. Journal of Cancer. 9(7). 1135–1144. 7 indexed citations
13.
Gu, Jie, Wei Mao, Fengkai Xu, et al.. (2018). Ubiquitin-protein ligase E3C maintains non-small-cell lung cancer stemness by targeting AHNAK-p53 complex. Cancer Letters. 443. 125–134. 48 indexed citations
14.
Lu, Chunlai, Di Ge, Yunfeng Yuan, et al.. (2016). Pedicle muscle flap transposition for chronic empyema with persistent bronchopleural fistula: experience of a single clinical center in China. Surgery Today. 46(10). 1132–1137. 9 indexed citations
15.
Guo, Jing, Jie Gu, Zongwu Lin, et al.. (2015). Regulation of CXCR4/AKT-signaling-induced cell invasion and tumor metastasis by RhoA, Rac-1, and Cdc42 in human esophageal cancer. Tumor Biology. 37(5). 6371–6378. 27 indexed citations
16.
Gu, Jie, Fengkai Xu, Guangyin Zhao, et al.. (2015). Capn4 promotes non-small cell lung cancer progression via upregulation of matrix metalloproteinase 2. Medical Oncology. 32(3). 51–51. 25 indexed citations
17.
Lu, Chunlai, Fengkai Xu, Jie Gu, et al.. (2015). Clinical and biological significance of stem-like CD133+CXCR4+ cells in esophageal squamous cell carcinoma. Journal of Thoracic and Cardiovascular Surgery. 150(2). 386–395. 38 indexed citations
18.
Liu, Ronghua, Jie Gu, Pei Jiang, et al.. (2014). DNMT1–MicroRNA126 Epigenetic Circuit Contributes to Esophageal Squamous Cell Carcinoma Growth via ADAM9–EGFR–AKT Signaling. Clinical Cancer Research. 21(4). 854–863. 95 indexed citations
19.
Lin, Zongwu, Jie Gu, Ronghua Liu, et al.. (2014). Genome-wide screening and co-expression network analysis identify recurrence-specific biomarkers of esophageal squamous cell carcinoma. Tumor Biology. 35(11). 10959–10968. 7 indexed citations
20.
Zhao, Guangyin, Zongwu Lin, Chunlai Lu, et al.. (2014). USP7 overexpression predicts a poor prognosis in lung squamous cell carcinoma and large cell carcinoma. Tumor Biology. 36(3). 1721–1729. 68 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mingjun Zheng Breakdown of academic impact, for papers by Maria O. Hernandez Breakdown of academic impact, for papers by Chengli Du Breakdown of academic impact, for papers by Massimiliano Mellone Breakdown of academic impact, for papers by Yongshuo Liu Breakdown of academic impact, for papers by Madelon Paauwe Breakdown of academic impact, for papers by Cheng Zhou Breakdown of academic impact, for papers by Rongfa Yuan Breakdown of academic impact, for papers by Wenwei Zhu Breakdown of academic impact, for papers by Qing‐Mei He
Rankless by CCL
2026